JP4809225B2 - 獣医学および医学用途のための組成物 - Google Patents
獣医学および医学用途のための組成物 Download PDFInfo
- Publication number
- JP4809225B2 JP4809225B2 JP2006524171A JP2006524171A JP4809225B2 JP 4809225 B2 JP4809225 B2 JP 4809225B2 JP 2006524171 A JP2006524171 A JP 2006524171A JP 2006524171 A JP2006524171 A JP 2006524171A JP 4809225 B2 JP4809225 B2 JP 4809225B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- och
- dialdehyde
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 63
- 150000001875 compounds Chemical class 0.000 claims abstract description 98
- 241001465754 Metazoa Species 0.000 claims abstract description 21
- 238000011282 treatment Methods 0.000 claims abstract description 19
- 235000019786 weight gain Nutrition 0.000 claims abstract description 15
- 230000004584 weight gain Effects 0.000 claims abstract description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 3
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 claims description 44
- 229920002201 Oxidized cellulose Polymers 0.000 claims description 42
- 229940107304 oxidized cellulose Drugs 0.000 claims description 42
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 26
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 24
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 claims description 21
- 241000894006 Bacteria Species 0.000 claims description 18
- 241000282412 Homo Species 0.000 claims description 16
- 230000007160 gastrointestinal dysfunction Effects 0.000 claims description 16
- 239000003674 animal food additive Substances 0.000 claims description 13
- -1 dialdehyde polysaccharides Chemical class 0.000 claims description 13
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 12
- 206010009887 colitis Diseases 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 229920001282 polysaccharide Polymers 0.000 claims description 10
- 239000005017 polysaccharide Substances 0.000 claims description 10
- 208000011231 Crohn disease Diseases 0.000 claims description 9
- 239000003242 anti bacterial agent Substances 0.000 claims description 9
- 229940088710 antibiotic agent Drugs 0.000 claims description 9
- 230000007863 steatosis Effects 0.000 claims description 9
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 230000001737 promoting effect Effects 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- 239000000178 monomer Substances 0.000 claims description 6
- 206010010774 Constipation Diseases 0.000 claims description 5
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 5
- 208000025865 Ulcer Diseases 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 231100000397 ulcer Toxicity 0.000 claims description 5
- 229930191978 Gibberellin Natural products 0.000 claims description 4
- 229920001503 Glucan Polymers 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 239000003793 antidiarrheal agent Substances 0.000 claims description 4
- 239000003448 gibberellin Substances 0.000 claims description 4
- 239000013003 healing agent Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 241000251468 Actinopterygii Species 0.000 claims description 3
- 241000282472 Canis lupus familiaris Species 0.000 claims description 3
- 241000938605 Crocodylia Species 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 241000282326 Felis catus Species 0.000 claims description 3
- 241000288906 Primates Species 0.000 claims description 3
- 241000283984 Rodentia Species 0.000 claims description 3
- 230000002421 anti-septic effect Effects 0.000 claims description 3
- 229940064004 antiseptic throat preparations Drugs 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 102000038379 digestive enzymes Human genes 0.000 claims description 3
- 108091007734 digestive enzymes Proteins 0.000 claims description 3
- 239000007884 disintegrant Substances 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- IXORZMNAPKEEDV-OBDJNFEBSA-N gibberellin A3 Chemical class C([C@@]1(O)C(=C)C[C@@]2(C1)[C@H]1C(O)=O)C[C@H]2[C@]2(C=C[C@@H]3O)[C@H]1[C@]3(C)C(=O)O2 IXORZMNAPKEEDV-OBDJNFEBSA-N 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 244000144977 poultry Species 0.000 claims description 3
- 239000000375 suspending agent Substances 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- 239000000080 wetting agent Substances 0.000 claims description 3
- 241000283690 Bos taurus Species 0.000 claims description 2
- 241000282994 Cervidae Species 0.000 claims description 2
- 241000238424 Crustacea Species 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 241000237852 Mollusca Species 0.000 claims description 2
- 241001494479 Pecora Species 0.000 claims description 2
- 229940125714 antidiarrheal agent Drugs 0.000 claims description 2
- 235000008216 herbs Nutrition 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 239000001254 oxidized starch Substances 0.000 claims description 2
- 235000013808 oxidized starch Nutrition 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims 4
- ABADUMLIAZCWJD-UHFFFAOYSA-N 1,3-dioxole Chemical group C1OC=CO1 ABADUMLIAZCWJD-UHFFFAOYSA-N 0.000 claims 2
- 239000006172 buffering agent Substances 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 239000003623 enhancer Substances 0.000 claims 2
- 125000000466 oxiranyl group Chemical group 0.000 claims 2
- 241000282887 Suidae Species 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- IXORZMNAPKEEDV-UHFFFAOYSA-N gibberellic acid GA3 Natural products OC(=O)C1C2(C3)CC(=C)C3(O)CCC2C2(C=CC3O)C1C3(C)C(=O)O2 IXORZMNAPKEEDV-UHFFFAOYSA-N 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 abstract description 8
- 230000036541 health Effects 0.000 abstract description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 5
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical group 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 229940093265 berberine Drugs 0.000 description 25
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 25
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 24
- 239000003599 detergent Substances 0.000 description 16
- 241000287828 Gallus gallus Species 0.000 description 13
- 235000013330 chicken meat Nutrition 0.000 description 13
- 210000001035 gastrointestinal tract Anatomy 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 8
- 206010012735 Diarrhoea Diseases 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000002775 capsule Substances 0.000 description 6
- 241000282898 Sus scrofa Species 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- 229960003022 amoxicillin Drugs 0.000 description 4
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 206010034133 Pathogen resistance Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000004837 gut-associated lymphoid tissue Anatomy 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 240000006024 Lactobacillus plantarum Species 0.000 description 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000001262 anti-secretory effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 150000003836 berberines Chemical group 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 229930186959 gusanlung Natural products 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 229940117681 interleukin-12 Drugs 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 229940072205 lactobacillus plantarum Drugs 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 244000005706 microflora Species 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001374 post-anti-biotic effect Effects 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 244000161488 Berberis lycium Species 0.000 description 1
- 235000008130 Berberis lycium Nutrition 0.000 description 1
- 240000000724 Berberis vulgaris Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000037740 Coptis chinensis Species 0.000 description 1
- 229920002085 Dialdehyde starch Polymers 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000004258 Ethoxyquin Substances 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
- 206010020400 Hostility Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 201000009840 acute diarrhea Diseases 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003095 anti-phagocytic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- DECIPOUIJURFOJ-UHFFFAOYSA-N ethoxyquin Chemical compound N1C(C)(C)C=C(C)C2=CC(OCC)=CC=C21 DECIPOUIJURFOJ-UHFFFAOYSA-N 0.000 description 1
- 229940093500 ethoxyquin Drugs 0.000 description 1
- 235000019285 ethoxyquin Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 230000037219 healthy weight Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 244000000074 intestinal pathogen Species 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000003044 randomized block design Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 201000009881 secretory diarrhea Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003330 sporicidal effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940124594 traditional oriental medicine Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- UCRLQOPRDMGYOA-DFTDUNEMSA-L zinc;(4r)-4-[[(2s)-2-[[(4r)-2-[(1s,2s)-1-amino-2-methylbutyl]-4,5-dihydro-1,3-thiazole-4-carbonyl]amino]-4-methylpentanoyl]amino]-5-[[(2s,3s)-1-[[(3s,6r,9s,12r,15s,18r,21s)-3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-12-benzyl-15-[(2s)-butan-2-yl]-6-(carbox Chemical compound [Zn+2].C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC([O-])=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@H](CC([O-])=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 UCRLQOPRDMGYOA-DFTDUNEMSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/132—Heterocyclic compounds containing only one nitrogen as hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/195—Antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Birds (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Botany (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003904654 | 2003-08-28 | ||
| AU2003904654A AU2003904654A0 (en) | 2003-08-28 | Compositions for veterinary and medical applications | |
| AU2003904817 | 2003-09-04 | ||
| AU2003904817A AU2003904817A0 (en) | 2003-09-04 | Compositions for veterinary and medical applications | |
| PCT/AU2004/001151 WO2005020997A1 (en) | 2003-08-28 | 2004-08-26 | Compositions for veterinary and medical applications |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007504097A JP2007504097A (ja) | 2007-03-01 |
| JP2007504097A5 JP2007504097A5 (enExample) | 2007-05-31 |
| JP4809225B2 true JP4809225B2 (ja) | 2011-11-09 |
Family
ID=34275842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006524171A Expired - Fee Related JP4809225B2 (ja) | 2003-08-28 | 2004-08-26 | 獣医学および医学用途のための組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8927565B2 (enExample) |
| EP (1) | EP1663225B1 (enExample) |
| JP (1) | JP4809225B2 (enExample) |
| CN (1) | CN101984976A (enExample) |
| AT (1) | ATE519487T1 (enExample) |
| CA (1) | CA2536489C (enExample) |
| DK (1) | DK1663225T3 (enExample) |
| PT (1) | PT1663225E (enExample) |
| WO (1) | WO2005020997A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE519487T1 (de) | 2003-08-28 | 2011-08-15 | Australian Biomedical Company Pty Ltd | Zusammensetzungen für veterinärmedizinische und medizinische anwendungen |
| WO2011070565A1 (en) * | 2009-12-07 | 2011-06-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Glucans for treating or preventing food sensitivity |
| KR101656929B1 (ko) | 2014-06-02 | 2016-09-13 | 씨제이제일제당 (주) | 반추동물의 메탄 생성 저감용 사료 첨가제 조성물 |
| CN119699475A (zh) * | 2017-03-28 | 2025-03-28 | Irp健康股份有限公司 | 小檗碱生物碱在预防和/或治疗肠疾病中的作用 |
| EP3398448A1 (en) * | 2017-05-05 | 2018-11-07 | Vall Garraf, S.L. | Fattening additive for animal nutritional composition |
| WO2025165991A1 (en) * | 2024-01-31 | 2025-08-07 | The Penn State Research Foundation | Biopolymeric anti-antibiotics and methods for making and using the same |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07504171A (ja) * | 1992-02-18 | 1995-05-11 | ユリキャップ コーポレイション | Ｈ．ｐｙｌｏｒｉ及び皮膚炎の治療方法および組成物 |
| JPH09187229A (ja) * | 1996-01-10 | 1997-07-22 | Idemitsu Material Kk | 家禽用飼料組成物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2801216A (en) | 1956-04-05 | 1957-07-30 | Union Carbide & Carbon Corp | Treatment of water with dialdehyde bactericides |
| US3016328A (en) | 1961-01-03 | 1962-01-09 | Ethicon Inc | Dialdehyde alcoholic sporicidal composition |
| US3679792A (en) | 1969-09-05 | 1972-07-25 | Wrigley W M Jun Co | Dialdehyde-containing anti-caries chewing gum compositions |
| US4034084A (en) * | 1974-10-10 | 1977-07-05 | Personal Products Company | Method of inhibiting microbial activity using insoluble dialdehyde polysaccharides |
| JPS621277A (ja) | 1985-06-27 | 1987-01-07 | Agency Of Ind Science & Technol | 化合物半導体装置 |
| JPH0633259B2 (ja) * | 1985-07-09 | 1994-05-02 | 生体機能利用化学品新製造技術研究組合 | ベルベリンアルカロイドの分離精製法 |
| AUPN327695A0 (en) | 1995-05-30 | 1995-06-22 | Chemeq Pty. Limited | Chemotherapeutic compositions |
| WO1998001039A1 (en) * | 1996-07-08 | 1998-01-15 | Idemitsu Materials Co., Ltd. | Feed composition for poultry |
| CN1193471A (zh) * | 1997-03-14 | 1998-09-23 | 赵海波 | 一种快速营养饲料添加剂 |
| WO2000003723A1 (en) | 1998-07-17 | 2000-01-27 | Chemeq Limited | Polymeric compounds and methods of formulating same |
| ES2369138T3 (es) | 2003-08-28 | 2011-11-25 | Australian Biomedical Company Pty Ltd | Composiciones para aplicaciones veterinarias y médicas. |
| ATE519487T1 (de) | 2003-08-28 | 2011-08-15 | Australian Biomedical Company Pty Ltd | Zusammensetzungen für veterinärmedizinische und medizinische anwendungen |
| AU2004267873C1 (en) | 2003-08-28 | 2008-12-11 | IRP Health Pty Ltd | Compositions for veterinary and medical applications |
-
2004
- 2004-08-26 AT AT04761188T patent/ATE519487T1/de active
- 2004-08-26 JP JP2006524171A patent/JP4809225B2/ja not_active Expired - Fee Related
- 2004-08-26 US US10/570,509 patent/US8927565B2/en active Active
- 2004-08-26 CA CA2536489A patent/CA2536489C/en not_active Expired - Fee Related
- 2004-08-26 WO PCT/AU2004/001151 patent/WO2005020997A1/en not_active Ceased
- 2004-08-26 EP EP04761188A patent/EP1663225B1/en not_active Expired - Lifetime
- 2004-08-26 DK DK04761188.4T patent/DK1663225T3/da active
- 2004-08-26 PT PT04761188T patent/PT1663225E/pt unknown
- 2004-08-26 CN CN2010102999835A patent/CN101984976A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07504171A (ja) * | 1992-02-18 | 1995-05-11 | ユリキャップ コーポレイション | Ｈ．ｐｙｌｏｒｉ及び皮膚炎の治療方法および組成物 |
| JPH09187229A (ja) * | 1996-01-10 | 1997-07-22 | Idemitsu Material Kk | 家禽用飼料組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20070027176A1 (en) | 2007-02-01 |
| DK1663225T3 (da) | 2011-11-21 |
| CN101984976A (zh) | 2011-03-16 |
| WO2005020997A1 (en) | 2005-03-10 |
| CA2536489A1 (en) | 2005-03-10 |
| EP1663225A4 (en) | 2009-04-29 |
| EP1663225B1 (en) | 2011-08-10 |
| CA2536489C (en) | 2012-07-03 |
| PT1663225E (pt) | 2011-09-05 |
| ATE519487T1 (de) | 2011-08-15 |
| EP1663225A1 (en) | 2006-06-07 |
| US8927565B2 (en) | 2015-01-06 |
| JP2007504097A (ja) | 2007-03-01 |
| HK1096586A1 (en) | 2007-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103006792B (zh) | 一种防治畜禽肠道疾病的中兽药及其制备方法与饲料 | |
| CN103989728B (zh) | 一种含有含珠草和β‑内酰胺类抗菌药的畜禽用复方药物 | |
| CN111705042B (zh) | 一株巴氏杆菌噬菌体vB_PmuP_PS02、其噬菌体组合物及其应用 | |
| CN103989725A (zh) | 一种含有含珠草和阿米卡星的畜禽用复方药物 | |
| CN114711336A (zh) | 避免抗微生物剂抗性的抗腹泻制剂 | |
| CN102988363B (zh) | 一种治疗家禽腺胃炎和坏死性肠炎的药物及其制备方法 | |
| CN103989729A (zh) | 一种含有含珠草和磺胺间甲氧嘧啶钠的畜禽用复方药物 | |
| JP4809225B2 (ja) | 獣医学および医学用途のための組成物 | |
| CN103989727A (zh) | 一种含有含珠草和痢菌净的畜禽用复方药物 | |
| CN104435023B (zh) | 一种中药提取物及其应用 | |
| CN102973690A (zh) | 一种治疗猪肠炎的中草药制剂 | |
| AU2004267873B2 (en) | Compositions for veterinary and medical applications | |
| ES2369138T3 (es) | Composiciones para aplicaciones veterinarias y médicas. | |
| CN113577112B (zh) | 一种防治禽沙门氏菌病的药物组合物及制备方法 | |
| CN101129379A (zh) | 抗球虫药物组合物及其制备方法 | |
| CN108815151A (zh) | 月桂酰精氨酸乙酯作为饲料添加剂的用途 | |
| CN104688883B (zh) | 一种含地锦草苦参和黄芩的中药组合物及其制备方法 | |
| HK1155383A (en) | Compositions for veterinary and medical applications | |
| HK1096586B (en) | Compositions for veterinary and medical applications | |
| CN111588773B (zh) | 通过母猪服药防治新生仔猪腹泻的中药组合物及其应用 | |
| CN107801854A (zh) | 一种用于预防仔猪白痢的哺乳母猪饲料添加剂 | |
| CN117244002A (zh) | 治腹泻兽用制剂 | |
| CN110051724A (zh) | 一种抗球虫中药复方及其应用 | |
| CN117883533A (zh) | 一种抗球虫病促生长的中药复方及其制备和应用 | |
| CN115554339A (zh) | 一种防治动物腹泻的药物组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070330 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070330 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100803 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101102 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20110801 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110805 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110818 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140826 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4809225 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| LAPS | Cancellation because of no payment of annual fees |